Edgewise Therapeutics(EWTX) - 2025 Q1 - Quarterly Results

News Release Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public of ering; pro-forma cash balance exceeds$624 million – Exhibit 99.1 – On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy ( ...